Literature DB >> 2702481

The development of neurogenic plasma extravasation in the rat dura mater does not depend upon the degranulation of mast cells.

S Markowitz1, K Saito, M G Buzzi, M A Moskowitz.   

Abstract

Mast cells were visualized in stretch preparations of the rat dura mater and were found mostly in relation to small and large blood vessels. The overall number of dural mast cells was unaffected by electrical trigeminal or chemical deafferentation. As in other tissues, mast cell degranulation increased at sites of local injury (electrode penetration) or after systemic treatment with compound 48/80. However, mast cells did not degranulate following electrical trigeminal stimulation, or after injection of drugs (capsaicin or substance P) which promote plasma extravasation in the dura. Furthermore, pretreatment with a mast cell stabilizer (sodium dicromoglycate) or with large doses of H1 and H2 histamine receptor blockers (mepyramine and cimetidine), did not block electrically- or chemically-induced neurogenic plasma extravasation (NPE). Daily pretreatment with 48/80 however completely attenuated or abolished NPE. Taken together these data suggest that as assessed by the extrusion of metachromatic granules, mast cells are not essential to the development of neurogenic inflammation within the rat dura mater. However, these findings cannot exclude the possibility that mast cells may amplify or modulate this process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702481     DOI: 10.1016/0006-8993(89)91403-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Interactions of mast cells with the nervous system--recent advances.

Authors:  D Johnson; W Krenger
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

Review 2.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 3.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 4.  Modelling headache and migraine and its pharmacological manipulation.

Authors:  S E Erdener; T Dalkara
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Pathophysiology of Migraine: A Disorder of Sensory Processing.

Authors:  Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

6.  Mast cell degranulation activates a pain pathway underlying migraine headache.

Authors:  Dan Levy; Rami Burstein; Vanessa Kainz; Moshe Jakubowski; Andrew M Strassman
Journal:  Pain       Date:  2007-04-24       Impact factor: 6.961

7.  Severe Headache or Migraine History is Inversely Correlated With Dietary Sodium Intake: NHANES 1999-2004.

Authors:  Janice M Pogoda; Noah B Gross; Xianghong Arakaki; Alfred N Fonteh; Robert P Cowan; Michael G Harrington
Journal:  Headache       Date:  2016-03-26       Impact factor: 5.887

8.  Pulsed estrogen therapy prevents post-OVX porcine dura mater microvascular network weakening via a PDGF-BB-dependent mechanism.

Authors:  Olga V Glinskii; Virginia H Huxley; Vladimir V Glinskii; Leona J Rubin; Vladislav V Glinsky
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 9.  Roads Less Traveled: Sexual Dimorphism and Mast Cell Contributions to Migraine Pathology.

Authors:  Andrea I Loewendorf; Anna Matynia; Hakob Saribekyan; Noah Gross; Marie Csete; Mike Harrington
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.